Anteris Technologies Global Corp.
$9.60
The Read: AVR's stock has historically surged on clinical milestones and clear financial guidance, as seen after Q4 2025 earnings and Q1 2026 trial progress, but has sharply declined—up to about 28%—when high cash burn and absent interim data overshadowed these advances.
Price
Overlays
Panel
AVR
Hover to view data
No Data